... Chapter 35 Nanoemulsion Formulations for Tumor- Targeted Delivery 723 Sandip B Tiwari and Mansoor M Amiji Chapter 36 SolidLipidNanoparticlesfor Antitumor DrugDelivery ... circulating half-lives in serum.28 Solidlipid nanoparticles, nanostructure lipid carriers, and lipiddrug conjugate nanoparticles have also been described for the drugdelivery strategies that could ... Polymeric nanoparticles are also mutable for enhancement of retention at the local tumor site and to combine anti- tumor agents with antiangiogenesis strategies.24–26 In addition to delivery of anti- tumor...
... with three antibody preparations: 1) primary antibody- the CA-125 monoclonal antibody, 2) linking antibody used to bind the primary antibody, 3) labeling Page of 11 (page number not for citation ... The polymerase chain reaction (PCR) was carried out for 30 cycles (98°C for 15 sec, 58°C for 30 sec, and 72°C for 40 sec and finally 72°C for min) The integrity of the cDNA was assayed by RTPCR ... Luc-H19 (control group) were performed at days 10, 12, 14 and 16 after cell inoculation Tumor dimensions were measured, and the tumor volume was calculated according to the formula (width)2 × length...
... Samples of the tumors were fixed in 4% buffered formaldehyde and processed for histological examination for evidence of necrosis and persistent tumor Computerized measurements of tumor surface ... Samples of the tumors were fixed in 4% buffered formaldehyde and processed for histological examination for evidence of necrosis and persistent tumor Computerized measurements of tumor surface ... ISH was performed on successive slides of TCC tissue for H19 and IGF2-P4 transcripts The intensity of hybridization signal was indicated as (0) for no staining, (+1) for weak, (+2) for moderate...
... the tumor microenvironment Recent studies have shown that curcumin possesses anti- tumor action through modulation of some essential components of the tumor microenvironment that regulates tumor ... has been implicated in cellular transformation, tumor promotion, angiogenesis, and tumor invasion and metastasis.17 One mechanism that may play a role in the anticancer properties of curcumin may ... new strategies for effective delivery of curcumin are being investigated.51 Among these methods, there are liposomal curcumin formulations and encapsulation in diverse polymeric nanoparticles. 14,22,51...
... phenotypes Table 3A: SAR for CB29 analogs .61 Table 3B: SAR for CB29 analogs 62 Table 4: SAR for CB7 analogs 65 Table 5: Refinement statistics for CB29 bound to ALDH3A1 ... contributor for Aldefluor activity as well (van den Hoogen et al., 2010) Another study with breast cancer patient tumor samples isolated for Aldefluor positive and Aldefluor negative tumor cells ... were selected for IC50 determination IC50 values were further determined against propionaldehyde oxidation (for ALDH1A1 and ALDH2) or benzaldehyde oxidation (for ALDH3A1) This was performed spectrophotometrically...
... other lipid- based carriers such as lipid emulsions, and lipid- drug complexes; also included are micelles, polymerdrug conjugates and immunoconjugates The potential of using drugdelivery systems for ... polymeric drugdelivery systems based on hydrogels, nanoparticles, microspheres, and lipid- based drugdelivery systems (e.g liposomes and microemulsions) have been developed for oral protein delivery ... a major challenge for its clinical application Immune response can arise as anti- therapeutic protein antibodies (anti- drug antibodies) can development during treatment These antibodies can either...
... Journal of Oncology 35: 1463-1471, 2009 Lipid- Based Nanoparticulate Systems for the Delivery of Anti- Cancer Drug Cocktails: Implications on Pharmacokinetics and Drug Toxicities Gigi N.C Chiu, Man-Yi ... Thank you for calling me every week without fail I want to thank them for their patience, especially in waiting for me to graduate Last but not least, I want to thank God for everything, for His ... Shiau Fui, whom I have known for more than 15 years now Thank you all for i always being there for me and encouraging me through emails Thanks for all the fun and for speaking the same lingo as...
... 75 Nanoshells (Gold-silica) (~130) Gold nanoparticles (10–40) Nanocages (30–40) No drug (for photothermal therapy) No drug (for photothermal ablation) No drug 37, 103 104 90, 105 Dendrimers (~ ... Adsorption of anti- neoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum J Pharm Sci 68, 1521–1524 (1979) 63 Couvreur, P et al Tissue distribution of anti- tumor drugs ... internalization properties for prostate cancer cells33 It is possible to increase the efficacy of antibodies by conjugating a therapeutic agent directly to it for targeted deliveryFor example, in 2000,...
... fewer side effects for women undergoing radiation therapy for carcinomas of the uterine cervix [175], for patients undergoing radiation therapy for head and neck cancers [176], and for colorectal ... the major circulating form of vitamin D, 25(OH)D, into the active hormonal form, 1,25(OH)2D So, there is a local mechanism in many tissues of the body for converting the form of vitamin D in the ... compared to 195 days for the control group [162] The second trial also showed that the probiotics worked better than the placebo, except for multiple recurring tumors [163] Except for the two studies...
... available tumor- associated serum biomarkers, such as carcinoembryonic antigen (CEA) for colon cancer, alpha-fetoprotein (AFP) for liver cancer, prostate-specific antigen for prostate cancer, cancer antigen ... (2003) Role of heat shock protein in chaperoning tumor antigens and modulating anti- tumor immunity In Tumor Antigens Recognized by T Cells and Antibodies (Stauss H, Kawakami Y & Parmiani G eds), ... these antigens are TAAs that are essential fortumor growth and have homogenous expression in the tumor tissues [245] On a similar note, the antigenic peptides could also be used to design drugs...
... neuropathological events and drug resistance in human tumour cells Therefore, it seems to be an attractive target for a combined chemopreventative ⁄ chemotherapeutic approach, which seems ideal for cancer therapy ... represents a promising starting point for designing and developing novel anticancer drugs 5520 Acknowledgements The authors wish to thank Dr Matteo Mozzicafreddo for technical assistance References ... novel anticancer agents Drug Resist Update 2, 215–223 24 Landis-Piwowar KR, Milacic V, Chen D, Yang H, Zhao Y, Chan TH, Yan B & Dou QP (2006) The proteasome as a potential target for novel anticancer...
... duration, progression-free survival (PFS) and OS No formal statistical test was performed Block balanced randomization lists were performed for each center Evaluation of Activity and Toxicity ... outpatient basis Patients received antiemetics and granulocyte colonystimulating factor at the physicians' discretion Palliative and supportive treatment for tumor- related symptoms was administered ... setting or for metastatic disease No other anticancer treatments, with the exception of bisphosphonates and palliative radiotherapy of non target lesions, were allowed Page of (page number not for citation...
... prospect for generating anti- cancer chimeric T cells for use in cancer immunotherapy The target selected in the current work was CEA, a tumor- selective antigen Several possible mechanisms fortumor ... single chain antibody variable fragments for antigen recognition [1-6] Specifically, the Tbodies described recognize an antigen that is expressed selectively by cells in growing tumors A ANTIGEN PRESENTING ... presentation of a tumor antigen by tumor cells without the necessary co-stimulatory signal [23,24], suppression or anergy of tumor- infiltrating T-cells [25-29], inability of a tumor antigen to induce...
... prospect for generating anti- cancer chimeric T cells for use in cancer immunotherapy The target selected in the current work was CEA, a tumor- selective antigen Several possible mechanisms fortumor ... single chain antibody variable fragments for antigen recognition [1-6] Specifically, the Tbodies described recognize an antigen that is expressed selectively by cells in growing tumors A ANTIGEN PRESENTING ... presentation of a tumor antigen by tumor cells without the necessary co-stimulatory signal [23,24], suppression or anergy of tumor- infiltrating T-cells [25-29], inability of a tumor antigen to induce...
... Chen X, Huang Y, Liu Y: Novel mixed polymeric micelles for enhancing delivery of anticancer drug and overcoming multidrug resistance in tumor cell lines simultaneously Pharm Res 2010, 27:1498 ... given propofol formulations recover their righting reflex after 7.2 It was concluded that the time for the animals to lose and recover righting reflex was essentially the same for both formulations ... important for a drugdelivery system because one of the important differences between the in vitro and in vivo conditions is the dilution effect under in vivo administration In addition, the drugloaded...
... each formulation were evaluated by tumor inhibition rate, which was calculated by the following formula: inhibition rate = (tumor weight of test group - tumor weight of negative control group) /tumor ... amphiphilic and could solubilize lipids or insert into phospholipid membranes to destabilize them [32–34] When the micelles are injected into the blood fordrugdelivery or drug detoxification, detrimental ... the in vivo antitumor efficacy with the animal tumor models set up by inoculation of H22 human liver cancer cell by measuring tumor weight or relative tumor inhibition rate after tumor implantation...
... “withdrawal” of anti- estrogens without agonist activity [1,13] In an in-vitro study in MCF-7 cells by Masamura et al [14] long-term estrogen deprivation (akin to usage of antiestrogens in the form of ... treatment Patient and tumor characteristics are shown in Table Two patients were still on follow-up at analysis The results from “withdrawal” from different agents are shown in the Table Drugs prior to ... in-vivo study [12], athymic mice were transplanted with ER positive tumor cells and then exposed to tamoxifen or placebo The tumors regressed initially over months but started to grow towards...
... USA) was performed for cDNA synthesis The cycling parameters were 25°C for 10 minutes and 37°C for hours Page of 10 Real time RT-PCR analyses were used to determine mRNA expressions of tumor necrosis ... RNAtarget/ RNAGusB Positive cells for CD3, CD8 and CD 20 Immunohistochemical staining was performed on left ventricular sections using anti- CD3, anti- CD8 and antiCD20 The diffusely scattered positive ... examined with the use of fluorescence microscopy for PKH26 dye The sections were stained for hematoxylin and eosin Immunohistochemistry was performed for asarcomeric actin, von Willebrand factor...
... weekly for weeks of a week cycle mg/m2 [92] I Refractory solid tumors and lymphoid(22) Once weekly for weeks of a week cycle mg/m2 [90] I Refractory solid tumors and lymphoid(27) Once weekly for ... showed that oral ITF 2357 has anti- tumor activity and a good safety profile The drug warrants additional studies, alone and in combination, as salvage treatment for HL even with less advanced ... to inhibit HDACs, and has anti- tumor activity in many preclinical models [25,85-88] Clinical trial with this agent was first done in the patients with advanced solid tumors or lymphoma in 2005...
... target-specific drugdelivery systems, representing a strategy for enhancement of the therapeutic action of Rh2 (H2cit)4 without affecting normal cells Some anticancer drugs associated with magnetic nanoparticles ... (H2cit)4 Therefore, we suggest that Magh-Rh2(H2cit)4 and Lip-Magh-Rh2(H2cit)4 should be considered a suitable and effective platform fordrugdelivery systems that operate more specifically in tumor ... rhodium carboxylates are known for their capacity to unpair DNA bases and therefore inhibit DNA synthesis Their antitumor effect has already been studied on Ehrlich ascites tumor, P388 lymphocytic leukemia,...